Reumatología
Servicio
Oregon Health & Science University
Portland, Estados UnidosPublicaciones en colaboración con investigadores/as de Oregon Health & Science University (10)
2024
-
Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials
Seminars in Arthritis and Rheumatism, Vol. 65
-
OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments
Seminars in Arthritis and Rheumatism, Vol. 65
2023
-
Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial
Journal of Rheumatology, Vol. 50, Núm. 4, pp. 478-487
2021
-
Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach
Seminars in Arthritis and Rheumatism, Vol. 51, Núm. 3, pp. 593-600
-
European League against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance
Annals of the Rheumatic Diseases, Vol. 80, Núm. 6, pp. 775-781
2018
-
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
The Lancet, Vol. 391, Núm. 10136, pp. 2213-2224
2016
-
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
Annals of the Rheumatic Diseases, Vol. 75, Núm. 4, pp. 687-695
-
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
Annals of the Rheumatic Diseases, Vol. 75, Núm. 6, pp. 1133-1138
2013
-
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
Annals of the Rheumatic Diseases, Vol. 72, Núm. 4, pp. 482-492
2010
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Annals of the Rheumatic Diseases, Vol. 69, Núm. 6, pp. 964-975